ReviewDiabetes, metabolic syndrome and obesity : targets and therapy2026
Diabetes Mellitus in Patients with Schizophrenia: A Systematic Review and Meta-Analysis of Prevalence of Types and Risk Factors.
Review in Diabetes, metabolic syndrome and obesity : targets and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Schizophrenia is associated with an increased risk of diabetes mellitus (DM) and type 2 diabetes mellitus (T2DM), yet the overall burden and related risk factors remain incompletely characterized. Aim: This study aimed to estimate the prevalence of DM in overall and T2DM in patients with schizophrenia and to summarize associated risk factors. Methods: This PRISMA-guided systematic review and meta-analysis included observational studies reporting DM or T2DM in patients with schizophrenia. Databases were systematically searched. Pooled prevalence estimates were calculated using a random-effects model in CMA software. Heterogeneity was assessed using Cochran's Q test and I Results: Thirty-five studies involving 139,304 individuals were included, and 34 studies contributed to the meta-analysis. The pooled prevalence of DM was 10.4% (95% CI: 8.3-12.9%), and the pooled prevalence of T2DM was 13.2% (95% CI: 9.1-18.9%). Between-study heterogeneity was substantial for both outcomes (I Conclusion: Overall diabetes, particularly type 2 diabetes, is prevalent among patients with schizophrenia and associated with demographic, clinical, treatment-related, and medication-related risk factors. These findings support routine metabolic screening and early preventive interventions to reduce diabetes risk and improve health outcomes in this high-risk population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.